Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines

Research output: Contribution to journalReview ArticleScientificpeer-review

Abstract

Explosive growth of nanomedicines continues to significantly impact the therapeutic strategies for effective cancer treatment. Despite the significant progress in the development of advanced nanomedicines, successful clinical translation remains challenging. As cancer nanomedicine is a multidisciplinary field, the fundamental problem is that the knowledge gaps stem from different vantage points in the understanding of cancer nanomedicines. The complexities and heterogenecity of both nanomedicines and cancer are further demanding the integration of highly diverse expertise to develop clinically translatable cancer nanomedicines. This progress report aims to discuss the current understanding of cancer nanomedicines between different research areas in terms of nanoparticle engineering, formulation, tumor patho-physiology and clinical medicine, as well as to identify the knowledge gaps lying at the interface between the different fields of research in nanomedicine. Here we also highlight for the necessity to harmonize the multidisciplinary effort in the research of nanomedicines in order to bridge the knowledge and to advance the full understanding in cancer nanomedicines. A paradigm shift is needed in the strategic development of disease specific nanomedicines in order to foster the successful translation into clinic of future cancer nanomedicines.
Original languageEnglish
Article number1700432
JournalAdvanced Healthcare Materials
Volume7
Issue number1
Pages (from-to)1700432
Number of pages23
ISSN2192-2640
DOIs
Publication statusPublished - 10 Jan 2018
MoE publication typeA2 Review article in a scientific journal

Fields of Science

  • 317 Pharmacy
  • cancer therapy
  • EPR
  • nanomedicine
  • tumor microenvironments
  • tumor targeting
  • DRUG-DELIVERY SYSTEMS
  • CELL LUNG-CANCER
  • METASTATIC BREAST-CANCER
  • PEGYLATED LIPOSOMAL DOXORUBICIN
  • ALBUMIN-BOUND PACLITAXEL
  • PHASE-III TRIAL
  • MESOPOROUS SILICA NANOPARTICLES
  • TUMOR-TARGETED NANOMEDICINES
  • INTERSTITIAL FLUID PRESSURE
  • HIGH-THROUGHPUT SYNTHESIS

Cite this